Risk stratification of pulmonary arterial hypertension (PAH) associated with adult congenital heart disease (ACHD)
S. Ramjug (Manchester, United Kingdom), C. Billings (Sheffield, United Kingdom), S. Bowater (Birmingham, United Kingdom), A. Charalampopoulos (Sheffield, United Kingdom), P. Clift (Birmingham, United Kingdom), C. Elliot (Sheffield, United Kingdom), J. Hurdman (Sheffield, United Kingdom), P. Jenkins (Liverpool, United Kingdom), D. Kiely (Sheffield, United Kingdom), R. Lewis (Sheffield, United Kingdom), J. Oliver (Leeds, United Kingdom), I. Sabroe (Sheffield, United Kingdom), R. Condliffe (Sheffield, United Kingdom)
Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension
Disease area: Interstitial lung diseases, Pulmonary vascular diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Ramjug (Manchester, United Kingdom), C. Billings (Sheffield, United Kingdom), S. Bowater (Birmingham, United Kingdom), A. Charalampopoulos (Sheffield, United Kingdom), P. Clift (Birmingham, United Kingdom), C. Elliot (Sheffield, United Kingdom), J. Hurdman (Sheffield, United Kingdom), P. Jenkins (Liverpool, United Kingdom), D. Kiely (Sheffield, United Kingdom), R. Lewis (Sheffield, United Kingdom), J. Oliver (Leeds, United Kingdom), I. Sabroe (Sheffield, United Kingdom), R. Condliffe (Sheffield, United Kingdom). Risk stratification of pulmonary arterial hypertension (PAH) associated with adult congenital heart disease (ACHD). 498
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: